证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 通信 从海外云厂商财报看"算力信心" AI 发展的宏大叙事并未发生改变，其投资的持续性与确定性已在 CSP 巨 头财报中得到进一步印证。本周微软、Meta、亚马逊陆续发布财报，为 市场观察其在 AI 领域投资及进展提供新窗口。从下游应用看，AI 推动各 大企业相关业务增速明显，其业绩正逐步兑现；从投资侧看，Capex 仍 彰显对 AI 基础设施建设的强劲需求，AI 技术已从底层算力渗透到垂类应 用，商业化进程持续加速。 AI 对业绩贡献逐步兑现，Capex 持续印证高景气度。本周北美各 CSP 巨 头陆续公布财报，尽管关税政策导致宏观前景不明，但三家科技巨头财报 数据均给出超出市场预期的营收和净利润，且均表示 AI 对业绩增长起到 重要作用，未来仍将保持、甚至部分继续上调高水平资本支出： 我们认为，尽管受关税扰动市场仍存担忧，但 AI 本身需求并未变化。目 前正通过"资本开支扩张-商业化落地-业绩兑现"的正向循环持续发展， 未来伴随大模型技术突破、行业应用场景的持续拓展与业绩的逐步兑现， 算力产业链仍将保持高景气度，建议关 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 钢铁 约束供给扩大消费 行情回顾（4.28-4.30）： 中信钢铁指数报收 1,528.72 点，下跌 0.52%，跑输沪深 300 指数 0.09pct，位列 30 个中信 一级板块涨跌幅榜第 16 位。 重点领域分析： 投资策略：受假期影响本周交易日有限，海外交易市场贵金属价格出现一定的调整，黑色商 品则依然震荡。根据财联社，宝钢回应近期钢铁市场传闻行业将限产 5000 万吨以应对近年 来市场供需结构的变化是大概率事件，但随后黑色商品价格表现平淡，行业内对今年限产落 实疑虑较大。由于过去在执行中存在一定的落实障碍，加之今年的监督和奖惩还缺少更多的 细节，市场抱有一定的疑虑是正常的。中国"内卷"很大原因是由于地方政府尤其青睐重资 产的制造业，一是因为投资规模大，对 GDP 拉动作用明显；二是因为增值税在生产环节征 收，跟生产规模直接挂钩；三是因为制造业不仅可以吸纳从农业部门转移出的低技能劳动力， 也可以带动第三产业发展，增加相关税收。因为绝大多数税收征收自企业，且多在生产环节 征收，所以过去地方政府重视企业而相对轻视民生 ...

证券研究报告 | 年报点评报告 gszqdatemark 2025 05 05 年 月 日 华大智造（688114.SH） 25Q1 业绩短期承压，国产替代加速 2025 业绩可期 华大智造发布 2024 年度报告。2024 年公司实现营业收入 30.13 亿元，同比增长 3.48%；归母净利润-6.01 亿元，同比增长 1.10%；扣非后归母净利润-6.53 亿元， 同比增长 4.41%。分季度看，2024Q4 实现营业收入 11.43 亿元，同比增长 61.64%； 归母净利润-1.37 亿元，同比增长 66.45%；扣非后归母净利润-1.55 亿元，同比增 长 64.68%。 华大智造发布 2025 年度一季报。2025Q1 公司实现营业收入 4.55 亿元，同比下 滑 14.26%；归母净利润-1.33 亿元，同比增长 33.67%；扣非后归母净利润-1.45 亿元，同比增长 31.99%。 观点：2024 年基因测序仪业务稳健增长，测序仪装机进展顺利。2025Q1 收入 端因季节波动等因素影响短期承压，利润端表现优于收入端主要系降本增效驱动 期间费用率改善。海外本地化业务进展顺利，全球生产与服务能力 ...

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company has shown strong performance in overseas markets, with a revenue increase of 27.67% in 2024, while domestic revenue grew by 9.32% despite pricing pressures from procurement policies [2][3] - The company is expanding its high-end product offerings and increasing its market share in both domestic and international markets, with significant progress in the installation of high-end models [4] - Profit growth is lagging behind revenue growth due to fluctuations in gross margins influenced by procurement pressures [3] Financial Performance Summary - In 2024, the company achieved a total revenue of 45.35 billion yuan, a year-on-year increase of 15.41%, and a net profit of 18.28 billion yuan, up 10.57% [1] - The gross margin for 2024 was 72.07%, slightly down by 0.89 percentage points from the previous year, with a notable increase in the proportion of lower-margin equipment sales [2] - For Q1 2025, the company reported a revenue of 11.25 billion yuan, a 10.12% increase year-on-year, while net profit grew by 2.65% [1][3] Market Expansion and Product Development - The company has successfully increased its coverage in tier-three hospitals, reaching a coverage rate of 44.93% in the domestic market [4] - In 2024, the company installed 4,017 units in overseas markets, with high-end models accounting for 67.16% of installations [4] - The company is actively establishing subsidiaries in key international markets, including Indonesia, Malaysia, and Thailand, to enhance its global presence [4] Future Projections - Revenue projections for 2025-2027 are estimated at 51.58 billion yuan, 60.07 billion yuan, and 70.75 billion yuan, respectively, with expected growth rates of 13.7%, 16.5%, and 17.8% [4] - Net profit forecasts for the same period are 20.63 billion yuan, 24.27 billion yuan, and 28.74 billion yuan, with growth rates of 12.8%, 17.6%, and 18.4% [4]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global product layout [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2] - The company’s overseas revenue reached 2.220 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3] Future Projections - Revenue projections for 2025-2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, representing year-on-year growth rates of 19.9%, 22.5%, and 21.1% respectively. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% respectively [4][5]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company is expected to experience a gradual improvement in performance due to a recovery in bidding trends, despite short-term pressure in Q1 2025 caused by domestic policy disruptions and high base effects from the previous year [2][3] - The in-vitro diagnostics business is showing steady growth, while the high-end ultrasound A20 is driving growth in the medical imaging segment [2] - The company is projected to achieve revenue of CNY 400.23 billion, CNY 456.94 billion, and CNY 521.36 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 9.0%, 14.2%, and 14.1% [5] Summary by Sections Financial Performance - In 2024, the company achieved revenue of CNY 367.26 billion, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of CNY 116.68 billion, a growth of 0.74% [1] - For Q1 2025, the company reported revenue of CNY 82.37 billion, a decline of 12.12% year-on-year, and a net profit of CNY 26.29 billion, down 16.81% [1][2] Business Segments - The life information and support business generated revenue of CNY 135.57 billion, down 11.11% year-on-year, primarily due to domestic industry regulations and delays in bidding procurement [2] - The in-vitro diagnostics segment saw revenue of CNY 137.65 billion, an increase of 10.82%, with overseas growth exceeding 30% [2] - The medical imaging segment achieved revenue of CNY 74.98 billion, a growth of 6.60%, with overseas revenue increasing by over 15% [2] Market Trends - The company is witnessing a continuous increase in overseas revenue, which reached CNY 164.34 billion in 2024, a growth of 21.28%, accounting for approximately 45% of total revenue [4] - The domestic market is expected to recover as medical equipment update projects gradually commence, with monthly bidding data showing a sustained recovery trend [3] Profitability Forecast - The company’s gross margin for Q1 2025 was reported at 62.53%, a decrease of 3.43 percentage points year-on-year, influenced by price pressures on reagents and increased competition in the domestic medical equipment market [3]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical industry [10] Core Views - The pharmaceutical index increased by 0.49% during the week, outperforming both the ChiNext and CSI 300 indices, indicating a strong market performance [1][16] - The report emphasizes structural opportunities within the pharmaceutical sector, particularly in innovative drugs and weight-loss medications, despite overall disappointing quarterly results [2][3][18] - The outlook for 2025 is optimistic, with expectations of a favorable trading atmosphere and structural bull market likely [4][19] Summary by Sections Recent Performance - The A-share pharmaceutical index showed resilience, with strong performances from innovative drugs, weight-loss lines, and companies exceeding quarterly expectations [2][17] - The market's reaction to innovative drug data was more mature, reflecting increased confidence and trading activity [3][18] Future Outlook - Short-term strategies focus on deepening investments in innovative drugs and enhancing self-sufficiency in the supply chain [4][19] - The report outlines four main strategic areas for 2025: innovative drugs, self-sufficiency, new technologies, and integration of large and small companies [4][19] Strategy Configuration - For innovative drugs, recommended companies include BeiGene, Kelun, and Innovent Biologics among others [5][20] - Emphasis on self-sufficiency includes companies like BGI Genomics and Mindray Medical [6][21] - New technology investments focus on brain-computer interfaces and AI in healthcare, with companies like Yihua and JD Health highlighted [7][24] Financial Performance - The pharmaceutical sector's overall revenue decreased by 1.4% in 2024, with a more significant decline of 4.7% in Q1 2025 [27][28] - The report notes a significant increase in revenue for selected biotech companies, with total revenue reaching 28.36 billion yuan in 2024, a 51.79% increase year-on-year [30][37] R&D Investment - The report indicates that R&D expenditures in the biotech sector remained high, with total R&D costs of 54.01 billion yuan in 2024, reflecting ongoing cash pressure [40]

证券研究报告 | 行业点评 gszqdatemark 2025 05 04 年 月 日 房地产 重点标的 | 股票 | 股票 | 投资 | | EPS（元） | | | | | PE | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2024A | 2025E | 2026E | 2027E | 2024A | 2025E | 2026E | 2027E | | 001979.SZ | 招商蛇口 | 买入 | 0.45 | 0.49 | 0.55 | 0.62 | 21.50 | 18.61 | 16.55 | 14.76 | | 002244.SZ | 滨江集团 | 买入 | 0.82 | 0.90 | 0.95 | 0.99 | 12.20 | 11.57 | 10.92 | 10.50 | | 600048.SH | 保利发展 | 买入 | 0.42 | 0.43 | 0.47 | 0.53 | 19.90 | 19.60 | 17.75 | 15.92 | | 600325. ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical industry [10] Core Views - The pharmaceutical index increased by 0.49% during the week of April 28-30, outperforming both the ChiNext index and the CSI 300 index [1][16] - The report emphasizes a structural optimism in the pharmaceutical sector, particularly focusing on innovative drugs and the potential for significant opportunities despite overall market fluctuations [3][19] Summary by Sections Recent Performance - The A-share pharmaceutical index showed strong performance compared to the overall market, with notable gains in innovative drugs, weight-loss medications, and companies exceeding first-quarter expectations [2][17] - The market's reaction to innovative drugs has matured, with increased confidence following positive data releases from companies like Kangfang and Newnovel [3][18] Future Outlook - The report outlines a positive outlook for 2025, predicting a favorable trading atmosphere and structural bull market for the pharmaceutical sector [4][19] - Key strategies include focusing on innovative drugs, self-sufficiency in the supply chain, and new technologies such as brain-computer interfaces and AI in healthcare [4][19] Strategy Configuration - For innovative drugs, recommended companies include BeiGene, Kelun, and Innovent Biologics, among others [5][20] - Emphasis on self-sufficiency and supply chain restructuring with companies like BGI and Mindray Medical [6][21] - New technology investments focus on brain-computer interfaces and AI healthcare solutions, highlighting companies like Yihua and Meinian Health [7][24] Financial Performance - The pharmaceutical sector's overall revenue decreased by 1.4% in 2024, with a more significant decline of 4.7% in Q1 2025 [27][28] - The report notes a recovery in gross profit margins, stabilizing at 30.6% in Q1 2025 after a downward trend [27][28] Biotech Sector Insights - The biotech sector saw a significant revenue increase of 51.79% in 2024, with a total revenue of 28.36 billion yuan [30] - The report highlights a continued high cash pressure on biotech companies, with R&D expenses remaining stable around 54 billion yuan [40]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is transitioning its growth momentum towards the domestic market, with a notable decline in profitability due to subsidiary losses and convertible bond expenses [1] - The VIP board segment shows resilience with a revenue increase of 11.39% year-on-year, despite a slight decrease in average selling price [2] - The company is actively engaging in cash dividends and share buybacks to enhance shareholder returns [4] - The company is positioned as a leader in the vacuum insulation panel industry, with significant growth potential in both domestic and international markets [5] Financial Performance Summary - In 2024, the company reported revenue of 934 million yuan, an increase of 11.16% year-on-year, but a net profit decline of 27.27% to 77.16 million yuan [1] - The gross margin for 2024 was 29.12%, down 3.91 percentage points, attributed to a decrease in terminal average prices and rising raw material costs [3] - The operating cash flow for 2024 was 65.65 million yuan, a decrease of 12.67% year-on-year, primarily due to increased costs outpacing revenue growth [4] - The company forecasts net profits of 100 million yuan, 140 million yuan, and 170 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 25X, 17X, and 14X [5] Market Dynamics - The company’s domestic sales ratio increased to 56.91% in 2024, up 11.98 percentage points year-on-year, driven by domestic replacement policies [2] - The overall industry remains in a high demand phase, with the VIP board segment benefiting from both domestic and international market dynamics [2]